Shared and Drug-specific Effects of Atomoxetine and Methylphenidate on Inhibitory Brain Dysfunction in Medication-naive ADHD Boys

Overview

Journal Cereb Cortex

Publisher Oxford University Press

Specialty Neurology

Date 2012 Oct 11

PMID 23048018

Citations 56

Authors

Ana Cubillo

Anna B Smith

Nadia Barrett

Vincent Giampietro

Michael J Brammer

Andrew Simmons

Katya Rubia

Affiliations

Soon will be listed here.

Abstract

The stimulant methylphenidate (MPX) and the nonstimulant atomoxetine (ATX) are the most commonly prescribed medications for attention deficit hyperactivity disorder (ADHD). However, no functional magnetic resonance imaging (fMRI) study has as yet investigated the effects of ATX on inhibitory or any other brain function in ADHD patients or compared its effects with those of MPX. A randomized, double-blind, placebo-controlled, crossover pharmacological design was used to compare the neurofunctional effects of single doses of MPX, ATX, and placebo during a stop task, combined with fMRI within 19 medication-naive ADHD boys, and their potential normalization effects relative to 29 age-matched healthy boys. Compared with controls, ADHD boys under placebo showed bilateral ventrolateral prefrontal, middle temporal, and cerebellar underactivation. Within patients, MPX relative to ATX and placebo significantly upregulated right ventrolateral prefrontal activation, which correlated with enhanced inhibitory capacity. Relative to controls, both drugs significantly normalized the left ventrolateral prefrontal underactivation observed under placebo, while MPX had a drug-specific effect of normalizing right ventrolateral prefrontal and cerebellar underactivation observed under both placebo and ATX. The findings show shared and drug-specific effects of MPX and ATX on performance and brain activation during inhibitory control in ADHD patients with superior upregulation and normalization effects of MPX.

Citing Articles

Neuroimaging as a Tool for Advancing Pediatric Psychopharmacology.

Bartkoski M, Tumberger J, Martin L, Choi I, Lee P, Strawn J Paediatr Drugs. 2025; .

PMID: 39899194 DOI: 10.1007/s40272-025-00683-9.

Emotion dysregulation in adolescents is normalized by ADHD pharmacological treatment.

Kondi K, Takacs M, Kovacs-Posta E, Szajli C, Sebok-Welker T, Rethelyi J Borderline Personal Disord Emot Dysregul. 2025; 12(1):3.

PMID: 39894810 PMC: 11789310. DOI: 10.1186/s40479-024-00268-x.

Overlapping and differential neuropharmacological mechanisms of stimulants and nonstimulants for attention-deficit/hyperactivity disorder: a comparative neuroimaging analysis.

Pan N, Ma T, Liu Y, Zhang S, Hu S, Shekara A Psychol Med. 2025; :1-15.

PMID: 39806554 PMC: 11769909. DOI: 10.1017/S003329172400285X.

Translating Decades of Neuroscience Research into Diagnostic and Treatment Biomarkers for ADHD.

Loo S, Lenartowicz A, Norman L, Michelini G Adv Neurobiol. 2024; 40:579-616.

PMID: 39562458 DOI: 10.1007/978-3-031-69491-2_20.

Effects of fMRI neurofeedback of right inferior frontal cortex on inhibitory brain activation in children with ADHD.

Lukito S, Lam S, Criaud M, Westwood S, Kowalczyk O, Curran S Philos Trans R Soc Lond B Biol Sci. 2024; 379(1915):20230097.

PMID: 39428885 PMC: 11491852. DOI: 10.1098/rstb.2023.0097.

References

Konrad K, Neufang S, Fink G, Herpertz-Dahlmann B . Long-term effects of methylphenidate on neural networks associated with executive attention in children with ADHD: results from a longitudinal functional MRI study. J Am Acad Child Adolesc Psychiatry. 2007; 46(12):1633-41. DOI: 10.1097/chi.0b013e318157cb3b. View

Rubia K, Halari R, Mohammad A, Taylor E, Brammer M . Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011; 70(3):255-62. PMC: 3139835. DOI: 10.1016/j.biopsych.2011.04.018. View

Bridgett D, Walker M . Intellectual functioning in adults with ADHD: a meta-analytic examination of full scale IQ differences between adults with and without ADHD. Psychol Assess. 2006; 18(1):1-14. DOI: 10.1037/1040-3590.18.1.1. View

Costa A, Riedel M, Pogarell O, Menzel-Zelnitschek F, Schwarz M, Reiser M . Methylphenidate effects on neural activity during response inhibition in healthy humans. Cereb Cortex. 2012; 23(5):1179-89. DOI: 10.1093/cercor/bhs107. View

Peterson B, Potenza M, Wang Z, Zhu H, Martin A, Marsh R . An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry. 2009; 166(11):1286-94. PMC: 3289412. DOI: 10.1176/appi.ajp.2009.08050724. View

Behrmann M, Geng J, Shomstein S . Parietal cortex and attention. Curr Opin Neurobiol. 2004; 14(2):212-7. DOI: 10.1016/j.conb.2004.03.012. View

Nee D, Wager T, Jonides J . Interference resolution: insights from a meta-analysis of neuroimaging tasks. Cogn Affect Behav Neurosci. 2007; 7(1):1-17. DOI: 10.3758/cabn.7.1.1. View

Nakao T, Radua J, Rubia K, Mataix-Cols D . Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry. 2011; 168(11):1154-63. DOI: 10.1176/appi.ajp.2011.11020281. View

Lijffijt M, Kenemans J, ter Wal A, Quik E, Kemner C, Westenberg H . Dose-related effect of methylphenidate on stopping and changing in children with attention-deficit/hyperactivity disorder. Eur Psychiatry. 2005; 21(8):544-7. DOI: 10.1016/j.eurpsy.2005.04.003. View

10.

Bullmore E, Brammer M, Rabe-Hesketh S, Curtis V, Morris R, Williams S . Methods for diagnosis and treatment of stimulus-correlated motion in generic brain activation studies using fMRI. Hum Brain Mapp. 1999; 7(1):38-48. PMC: 6873318. View

11.

Chambers C, Garavan H, Bellgrove M . Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neurosci Biobehav Rev. 2008; 33(5):631-46. DOI: 10.1016/j.neubiorev.2008.08.016. View

12.

Rubia K, Smith A, Brammer M, Taylor E . Temporal lobe dysfunction in medication-naïve boys with attention-deficit/hyperactivity disorder during attention allocation and its relation to response variability. Biol Psychiatry. 2007; 62(9):999-1006. DOI: 10.1016/j.biopsych.2007.02.024. View

13.

Rubia K, Overmeyer S, Taylor E, Brammer M, Williams S, Simmons A . Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry. 1999; 156(6):891-6. DOI: 10.1176/ajp.156.6.891. View

14.

Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo M, Alda J . Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009; 25(11):2745-54. DOI: 10.1185/03007990903316152. View

15.

Aron A, Durston S, Eagle D, Logan G, Stinear C, Stuphorn V . Converging evidence for a fronto-basal-ganglia network for inhibitory control of action and cognition. J Neurosci. 2007; 27(44):11860-4. PMC: 6673355. DOI: 10.1523/JNEUROSCI.3644-07.2007. View

16.

Corbetta M, Shulman G . Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci. 2002; 3(3):201-15. DOI: 10.1038/nrn755. View

17.

Rubia K . "Cool" inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus "hot" ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a review. Biol Psychiatry. 2010; 69(12):e69-87. DOI: 10.1016/j.biopsych.2010.09.023. View

18.

Graf H, Abler B, Freudenmann R, Beschoner P, Schaeffeler E, Spitzer M . Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers. Biol Psychiatry. 2010; 69(9):890-7. DOI: 10.1016/j.biopsych.2010.10.018. View

19.

DeVito E, Blackwell A, Clark L, Kent L, Dezsery A, Turner D . Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD). Psychopharmacology (Berl). 2008; 202(1-3):531-9. PMC: 2704617. DOI: 10.1007/s00213-008-1337-y. View

20.

Gallezot J, Weinzimmer D, Nabulsi N, Lin S, Fowles K, Sandiego C . Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. Neuroimage. 2010; 56(1):268-79. PMC: 3710586. DOI: 10.1016/j.neuroimage.2010.09.040. View